Introduction: Serum prostate specific antigen PSA is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases is not fully established.
Patients with non-metastatic high-risk prostate cancer by bone and computerized tomography CT scan were randomly assigned to receive androgen deprivation therapy ADT and docetaxel plus estramustine or ADT alone. The relationship between PSA and outcomes was studied using residual-based approaches and spline functions. Results: The median follow-up was 12 years range: The year RFS rate was Exploratory analyses revealed no deviation from the linear relationship assumption between PSA and the log hazard of events.
Conclusions: Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy. Keywords: Docetaxel; Flexible modeling; Functional form; High-risk prostate cancer; Prostate specific antigen. Abstract Introduction: Serum prostate specific antigen PSA is a well-known prognostic parameter in men with prostate cancer.
